Chronic myeloid leukemia-transplantation in the tyrosine kinase era

Hematology/Oncology Clinics of North America

Volumn 28, Issue 6, 2014, Pages 1037-1053

  Innes, Andrew J ^a   Apperley, Jane F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Allogeneic stem cell transplant; Chronic myeloid leukemia; Tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DASATINIB; IMATINIB; IMMUNOLOGIC AGENT; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTHRALGIA; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DRUG ERUPTION; DRUG INDICATION; DRUG TREATMENT FAILURE; EDEMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUSCLE CRAMP; MYELOABLATIVE CONDITIONING; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL DEPLETION; TIME TO TREATMENT; TREATMENT INDICATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROCEDURES; REMISSION; TREATMENT OUTCOME;

BENZAMIDES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84912574732     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.08.002     Document Type: Review

References (62)

1. Goldman J.M. Chronic myeloid leukemia: a historical perspective. Semin Hematol 2010, 47:302-311.
2. Fefer A., Cheever M.A., Thomas E.D., et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. NEngl J Med 1979, 300:333-337.
3. Groffen J., Stephenson J.R., Heisterkarmp N., et al. Philadelphia chromosomal break points are clustered within a limited region, bcr. on chromosome 22. Cell 1984, 36:93-99.
4. Baccarani M., Saglio G., Goldman J., European LeukemiaNet, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
5. Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013, 2013(122):872-884.
6. Hanfstein B., Müller M.C., Hehlmann R., et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26:2096-2102.
7. Marin D., Ibrahim A.R., Lucas C., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. JClin Oncol 2012, 30:232-238.
8. Deininger M, O'Brien SG, Guilhot F. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. 2009 114: Abstract 1126.
9. Larson R.A., Hochhaus A., Hughes T.P., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012, 26:2197-2203.
10. Jabbour E., Kantarjian H.M., Saglio G., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
11. Cortes J.E., Kim D.W., Kantarjian H.M., et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. JClin Oncol 2012, 30:3486-3492.
12. Steegmann J.L., Cervantes F., le Coutre P., et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012, 53:2351-2361.
13. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEngl J Med 2010, 362:2251-2259.
14. Soverini S., Hochhaus A., Nicolini F.E., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011, 118:1208-1215.
15. Ernst T., La Rosée P., Müller M.C., et al. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011, 25:997-1008.
16. Shah N.P., Guilhot F., Cortes J.E., et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014, 123:2317-2324.
17. Giles F.J., le Coutre P.D., Pinilla-Ibarz J., et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013, 27:107-112.
18. Kim D.D., Lee H., Kamel-Reid S., et al. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 2013, 160:630-639.
19. Cortes J.E., Kim D.W., Pinilla-Ibarz J., et al. Aphase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. NEngl J Med 2013, 369:1783-1796.
20. Griesshammer M., Heinze B., Bangerter M., et al. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. JMol Med 1997, 75:836-838.
21. Hehlmann R. How I treat CML blast crisis. Blood 2012, 120:737-747.
22. Saussele S., Lauseker M., Gratwohl A., et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010, 115:1880-1885.
23. Silver R.T. The blast phase of chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:387-394.
24. Milojkovic D., Ibrahim A., Reid A., et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica 2012, 97:473-474.
25. Rea D., Etienne G., Nicolini F., et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 2012, 26:2254-2259.
26. Ohanian M., Kantarjian H.M., Quintas-Cardama A., et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 2014, 14:155-162.
27. Jiang Q., Xu L.P., Liu D.H., et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011, 117:3032-3040.
28. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998, 352:1087-1092.
29. Milojkovic D., Szydlo D., Hoek J., et al. Prognostic significance of EBMT score for chronic myeloid leukaemia patients in the era of tyrosine kinase inhibitor therapy: a retrospective study from the chronic malignancy working party of the European Group For Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2014, 49:S34-S35.
30. Passweg J.R., Walker I., Sobocinski K.A., et al. Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004, 125:613-620.
31. Rezvani K., Kanfer E.J., Marin D., et al. EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant 2012, 18:235-240.
32. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
33. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
34. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008, 112:1992-2001.
35. Zipperer E., Pelz D., Nachtkamp K., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732.
36. Pavlů J., Kew A.K., Taylor-Roberts B., et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010, 115:4018-4020.
37. Pavlů J., Szydlo R.M., Goldman J.M., et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned?. Blood 2011, 117:755-763.
38. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
39. Gratwohl A., Heim D. Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:431-443.
40. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008, 112:3500-3507.
41. Luo Y., Lai X.Y., Tan Y.M., et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009, 23:1171-1174.
42. Liu Q.F., Xu X.J., Chen Y.K., et al. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann Hematol 2011, 90:331-341.
43. Khoury H.J., Kukreja M., Goldman J.M., et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012, 47:810-816.
44. Zheng C., Tang B., Yao W., et al. Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage. Biol Blood Marrow Transplant 2013, 19:1708-1712.
45. Shimoni A., Leiba M., Schleuning M., et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia. Leukemia 2009, 23:190-194.
46. Copelan E.A., Crilley P.A., Szer J., et al. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:851-855.
47. Bacher U., Klyuchnikov E., Zabelina T., et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009, 88:1237-1247.
48. Sanz J., Montesinos P., Saavedra S., et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16:1589-1595.
49. Jabbour E., Cortes J., Santos F.P., et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011, 117:3641-3647.
50. Topcuoglu P., Arat M., Ozcan M., et al. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. Ann Hematol 2012, 91:577-586.
51. Zuckerman T., Katz T., Haddad N., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up. Am J Hematol 2012, 87:875-879.
52. Oyekunle A., Zander A.R., Binder M., et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 2013, 92:487-496.
53. Warlick E., Ahn K.W., Pedersen T.L., et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012, 119:4083-4090.
54. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
55. Olavarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
56. Uzunel M., Mattsson J., Brune M., et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003, 101:469-472.
57. Lin F., van Rhee F., Goldman J.M., et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplant. Blood 1996, 87:4473-4478.
58. Innes A.J., Lurkins J., Szydlo R. The majority of patients receiving donor lymphocyte infusions for relapsed chronic myeloid leukemia remain PCR positive despite maintaining long-term remission. Blood 2011, 118. Abstract 4103.
59. Innes A.J., Beattie R., Sergeant R., et al. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant 2013, 48:1324-1328.
60. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
61. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
62. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003, 17:1707-1712.